ライフサイエンスコーパス: tetrahydrocannabinol

1 n the pharmacological properties of Delta(9)-tetrahydrocannabinol.

2 uracy was significantly reduced after Delta9-tetrahydrocannabinol.

3 or marijuana's bioactive ingredient Delta(9)-tetrahydrocannabinol.

4 inuation of chronic heavy use of cannabis or tetrahydrocannabinol.

5 ediates the functional responses of Delta(9)-tetrahydrocannabinol.

6 and adolescent exposure to cannabis/delta-9-tetrahydrocannabinol.

7 diction for cocaine, amphetamine, and Delta9-tetrahydrocannabinol.

8 abinoid receptor 1 stimulation with Delta(9)-tetrahydrocannabinol.

9 pe for varieties complying with the Delta(9)-tetrahydrocannabinol 0.2% threshold.

10 icated by the exogenous cannabinoid Delta(9)-tetrahydrocannabinol (1 microM) nor reversed by the sele

11 rocannabinol (THC-COOH), 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC), and 11-nor-9-carboxy-D

12 lead compound, (-)-3-(1-adamantyl)-Delta(8)-tetrahydrocannabinol (1a, AM411), was found to have robu

13 This system can be activated by Delta(9)-tetrahydrocannabinol, a major drug of abuse.

14 Delta9-Tetrahydrocannabinol administration enhanced activity fo

15 Furthermore, chronic Delta(9)-tetrahydrocannabinol administration, which reduces canna

16 n the nucleus accumbens after acute Delta(9)-tetrahydrocannabinol administration.

17 Delta9-Tetrahydrocannabinol also attenuated the normal time-dep

18 al structures of human CB1 in complex with a tetrahydrocannabinol (AM11542) and a hexahydrocannabinol

19 A challenging step in the preparation of tetrahydrocannabinol analogs is an acid-catalyzed intram

20 efficacy and safety of nabilone, a synthetic tetrahydrocannabinol analogue, as a treatment for non-mo

21 imols (maximum daily dose, 86.4 mg of Delta9-tetrahydrocannabinol and 80 mg of cannabidiol) or placeb

22 to multiple compounds, particularly Delta-9-tetrahydrocannabinol and cannabidiol.

23 ecades, with particular emphasis on Delta(9)-tetrahydrocannabinol and cannabidiol.

24 Here we show that the cannabinoids Delta(9)-tetrahydrocannabinol and CP55940 decreased the power of

25 delta9-Tetrahydrocannabinol and endogenous cannabinoids (e.g.,

26 Trials assessing neuroprotection with tetrahydrocannabinol and lamotrigine are imminent; both

27 er States to monitor the content of Delta(9)-tetrahydrocannabinol and other cannabinoids in food and

28 owever, therapeutic applications of Delta(9)-tetrahydrocannabinol and other CB1 orthosteric receptor

29 Both Delta(9)-tetrahydrocannabinol and the endogenous ligand, anandami

30 was also demonstrated with CP55940, Delta(9)-tetrahydrocannabinol, and cannabidiol, thus suggesting t

31 f abuse including cocaine, ethanol, Delta(9)-tetrahydrocannabinol, and opiates; the antipsychotic dru

32 hydroxypropyl)cyclohexan-1-ol) and Delta(9)-tetrahydrocannabinol are orthosteric agonists for the re

33 t HU210, a structural analog of (-)-Delta(9)-tetrahydrocannabinol, binds to brain cannabinoid (CB1) r

34 e nucleus accumbens after exposure to Delta9-tetrahydrocannabinol, but less is known about cannabis u

35 for the motor-impairing activity of Delta(9)-tetrahydrocannabinol by inhibiting local autophagy.

36 binol, delta-9-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, cannabichromene, delta-9-tetrahydr

37 on three common cannabinoids, namely, Delta9-tetrahydrocannabinol, cannabidiol, and cannabinol.

38 wed male and female mice to consume Delta(9)-tetrahydrocannabinol, cannabidiol, or morphine ad libitu

39 ader (recreational) or more restrictive (low-tetrahydrocannabinol) cannabis laws were associated with

40 uana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a placebo capsule thre

41 0-CB1 receptor complex, and the (-)-Delta(9)-tetrahydrocannabinol-CB1 receptor complex, we found that

42 with users' urinary 11-nor-9-carboxy-Delta9-tetrahydrocannabinol concentrations at study entry.

43 ith high affinity and specificity for delta9-tetrahydrocannabinol could be valuable immunopharmacothe

44 ion phase from 5 mg to a maximum of 25 mg of tetrahydrocannabinol daily and a 10 week maintenance pha

45 cannabinoids such as cannabidiol or delta-9-tetrahydrocannabinol decreased the expression of AW11201

46 to the determination of cannabidiol, delta 8-tetrahydrocannabinol (delta 8-THC), delta 9-tetrahydroca

47 delta 9-Tetrahydrocannabinol (delta 9-THC) a prototypic compound

48 -tetrahydrocannabinol (delta 8-THC), delta 9-tetrahydrocannabinol (delta 9-THC), and cannabinol in pu

49 (QSAR) for the side-chain region of Delta(8)-tetrahydrocannabinol (Delta(8)-THC) analogues is reporte

50 nalogue of the phytocannabinoid (-)-Delta(8)-tetrahydrocannabinol (Delta(8)-THC), was shown to have i

51 55,212 (64%), anandamide (42%), and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (44%) all initiated

52 Additionally, the stability of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and cannabinol (CBN)

53 f antisense oligodeoxynucleotide to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other naturally

54 The memory-disruptive effects of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and the synthetic ca

55 ents following repeated exposure to Delta(9)-tetrahydrocannabinol (Delta(9)-THC) are associated with

56 nd 2 (CB1 and CB2) agonists such as Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can produce toleranc

57 Delta(9)-tetrahydrocannabinol (Delta(9)-THC) is an effective anti

58 d the acute, dose-related effects of delta-9-tetrahydrocannabinol (Delta(9)-THC) on psychophysiologic

59 The acute, dose-related effects of Delta-9-tetrahydrocannabinol (Delta(9)-THC) on the auditory stea

60 -occurring Cannabis sativa alkaloid Delta(9)-tetrahydrocannabinol (Delta(9)-THC) or the synthetic can

61 reported that intracerebellar (ICB) Delta(9)-tetrahydrocannabinol (Delta(9)-THC) produces dose-depend

62 is, which are attributed to action of Delta9-tetrahydrocannabinol (Delta(9)-THC), a cannabis constitu

63 determined by the concentration of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), a psychoactive cons

64 etween its psychoactive constituent, Delta-9-tetrahydrocannabinol (Delta(9)-THC), and CB(1) receptors

65 re sensitive to acutely administered delta-9-tetrahydrocannabinol (Delta(9)-THC), have delayed tolera

66 ychoactive ingredient of marijuana, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), increased GluR2-lac

67 constituent of Cannabis sativa L., Delta(9)-tetrahydrocannabinol (Delta(9)-THC), led to the identifi

68 he naturally occurring cannabinoid, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), releases dynorphin

69 Delta-9-tetrahydrocannabinol (Delta(9)-THC), the main psychoacti

70 widely used recreational agent, and Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the major active co

71 In contrast, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the major psychoact

72 ed in the psychotomimetic effects of delta-9-tetrahydrocannabinol (Delta(9)-THC), the principal activ

73 t of marijuana, the partial agonist Delta(9)-tetrahydrocannabinol (Delta(9)-THC).

74 In contrast to marijuana, where Delta(9)-tetrahydrocannabinol (Delta(9)THC) is metabolized to onl

75 al activation under the influence of delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD)

76 arijuana and its active constituent, delta-9-tetrahydrocannabinol (delta-9-THC), may reduce pain sens

77 investigated whether the effects of delta-9-tetrahydrocannabinol (delta-9-THC), the main psychoactiv

78 nnabigerol, cannabidiol, cannabinol, delta-9-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, cann

79 Chronic Delta9-tetrahydrocannabinol (Delta9-THC) administration produce

80 sativa and its principal components, Delta9-tetrahydrocannabinol (Delta9-THC) and cannabidiol, are i

81 A secondary analysis utilizing delta-9-tetrahydrocannabinol (Delta9-THC) as a positive control

82 Delta9-Tetrahydrocannabinol (delta9-THC) fails to inhibit EPSCs

83 eatment of SIV-infected macaques with Delta9-tetrahydrocannabinol (Delta9-THC) increased survival and

84 d macaques, chronic administration of Delta9-tetrahydrocannabinol (Delta9-THC) inhibited viral replic

85 Delta9-tetrahydrocannabinol (delta9-THC) is an effective anti-e

86 Delta9-tetrahydrocannabinol (Delta9-THC) is the principal psych

87 e concomitant increase in potency of delta-9-tetrahydrocannabinol (Delta9-THC) may have contributed t

88 o examine the effects of estrogen and delta9-tetrahydrocannabinol (delta9-THC) on learning and memory

89 were treated with escalating doses of Delta9-tetrahydrocannabinol (Delta9-THC) or R+-[2,3-dihydro-5-m

90 psychoactive ingredient in cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), affects the brain mai

91 psychoactive component of marijuana, Delta9-tetrahydrocannabinol (Delta9-THC), are presented.

92 Studies show that (-)- 9-tetrahydrocannabinol (Delta9-THC), the major psychoactiv

93 central hypothesis that exposure to Delta-9-tetrahydrocannabinol (Delta9-THC), the major psychoactiv

94 dysfunctional by chronic exposure to delta-9-tetrahydrocannabinol (Delta9-THC), the major psychoactiv

95 Delta9-Tetrahydrocannabinol (Delta9-THC), the major psychoactiv

96 improvement in affinity for (-)-trans-delta9-tetrahydrocannabinol (delta9-THC).

97 main active chemical in marijuana is delta9-tetrahydrocannabinol (delta9-THC); hence, monoclonal ant

98 ffects of intravenously administered delta-9-tetrahydrocannabinol (Delta9-THC; 1.19 mg/2 ml), the key

99 s with oral cannabis extract (n=211), Delta9-tetrahydrocannabinol (Delta9-THC; n=206), or placebo (n=

100 (-)-Delta9-Tetrahydrocannabinol ((-)-Delta9-THC) is the major activ

101 Bath applied Delta(9)-tetrahydrocannabinol depressed GABA cell activity, there

102 c syntheses of four photoswitchable Delta(9)-tetrahydrocannabinol derivatives (azo-THCs) from a centr

103 he CB(1) receptor agonist (-)-11-OH-Delta(9)-tetrahydrocannabinol dimethylheptyl.

104 vo exposure to the phytocannabinoid Delta(9)-tetrahydrocannabinol disrupts the intrasynaptic nanoscal

105 cannabis sales in Colorado (in kilograms of tetrahydrocannabinol) during that period.

106 (EC(50) = 3.7 microM), followed by Delta(9)-tetrahydrocannabinol (EC(50) = 14 microM) and cannabinol

107 Delta9-Tetrahydrocannabinol enhanced WM activity network-wide f

108 ptors, such as the phytocannabinoid Delta(9)-tetrahydrocannabinol, exert a remarkable array of therap

109 The CB(1) receptor agonist Delta(9)-tetrahydrocannabinol exerted a biphasic control of fear

110 active compound in herbal cannabis, Delta(9)-tetrahydrocannabinol, exerts all of its known central ef

111 ors, including CP55940, HU-210, and Delta(9)-tetrahydrocannabinol, failed to stimulate [(35)S]GTP gam

112 l (11-OH-THC), and 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol glucuronide (THC-COO-glu).

113 ychoactive ingredient in marijuana, Delta(9)-tetrahydrocannabinol, has been shown to inhibit adenylyl

114 Although cannabinoids, such as Delta(9)-tetrahydrocannabinol, have been studied extensively for

115 pal bioactive component of marijuana, delta9-tetrahydrocannabinol, have been used for thousands of ye

116 of cannabinoid agonists, including Delta(9)-tetrahydrocannabinol, HU-210, CP55,940, 2-arachidonoylgl

117 6) and (-)-11-hydroxydimethylheptyl-Delta(8)-tetrahydrocannabinol (HU210) were drastically reduced (5

118 pic and appetite-inducing component Delta(9)-tetrahydrocannabinol, i.e., the endocannabinoid 2-arachi

119 hanism for the addictive effects of Delta(9)-tetrahydrocannabinol in juvenile-adolescents, by potenti

120 Delta9-Tetrahydrocannabinol increased psychotic symptoms and le

121 a novelly identified TRPV2 agonist, Delta(9)-tetrahydrocannabinol, indicating that human TRPV2 is fun

122 ntion (with trehalose), rescued the Delta(9)-tetrahydrocannabinol-induced impairment of motor coordin

123 c agonist 1,1-dimethylbutyl-1-deoxy-Delta(9)-tetrahydrocannabinol (JWH133).

124 tally induced higher cannabinoid [(-)-Delta9-tetrahydrocannabinol] levels constrain preimplantation e

125 rticipants were randomly assigned to a 3.95%-tetrahydrocannabinol marijuana cigarette, a 2.5-mg drona

126 hy the closely-related psychoactive compound tetrahydrocannabinol may not have the same effects on th

127 We have previously reported that tetrahydrocannabinol-mediated cognitive impairment arise

128 ceptor agonism using R(+)-WIN 55,212, delta9-tetrahydrocannabinol, methanandamide and JWH-133 quantit

129 vestigated whether oral dronabinol (Delta(9)-tetrahydrocannabinol) might slow the course of progressi

130 logs of the cyclic ether O,2-propano-delta 8-tetrahydrocannabinol (O,2-propano-delta 8-THC) point to

131 But the variable effects of Delta(9)-tetrahydrocannabinol obscure the interpretation of these

132 Chronic injections of Delta(9)-tetrahydrocannabinol occluded LTD compared with vehicle

133 the brain's reward circuit, and how Delta(9)-tetrahydrocannabinol occludes this plasticity.

134 the use of e-cigarette cartridges containing tetrahydrocannabinol oil.

135 estigating effects of the eCB agonist Delta9-tetrahydrocannabinol on WM function in 17 healthy volunt

136 oyl glycerol, and the plant-derived Delta(9)-tetrahydrocannabinol, one of the main psychoactive compo

137 Rat dams were treated with Delta(9)-tetrahydrocannabinol or a synthetic cannabinoid during t

138 Exogenous cannabinoids, such as tetrahydrocannabinol, produce their biological effects t

139 ychoactive constituent of cannabis, Delta(9)-tetrahydrocannabinol, produces in humans subjective resp

140 ctive constituent of marijuana, (-)-Delta(9)-tetrahydrocannabinol, produces most of its physiological

141 of 89% of the patients reported having used tetrahydrocannabinol products in e-cigarette devices, al

142 se-contingent delivery of vaporized Delta(9)-tetrahydrocannabinol-rich (CAN(THC)) or cannabidiol-rich

143 Yet, contrary to Delta(9)-tetrahydrocannabinol, SCs may lead to severe health cons

144 cannabinoid agonists WIN 55,212-2 and delta9-tetrahydrocannabinol shortened the modal response time,

145 drawal in mice rendered tolerant to Delta(9)-tetrahydrocannabinol, suggesting that AM1710 is not a fu

146 ated cumulative lifetime exposure of Delta-9-tetrahydrocannabinol (THC) (mean 168 +/- 45 versus 244 +

147 oses (30-240 mug/kg) of intravenous Delta(9)-tetrahydrocannabinol (THC) administration on the perform

148 ch indicates that administration of Delta(9)-tetrahydrocannabinol (THC) alters threat perception and

149 xy-substituted hexahydrocannabinol (HHC) and tetrahydrocannabinol (THC) analogues in which a seven at

150 an increase of the psychoactive compound (9)-tetrahydrocannabinol (THC) and a decrease of the potenti

151 The plant-derived cannabinoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both ha

152 suggests that the phytocannabinoids Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differe

153 Delta(9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD) occur n

154 Activity is primarily through 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) via can

155 ids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have b

156 s isolated from cannabis, including Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD).

157 icinal applications of pure forms of delta-9-tetrahydrocannabinol (THC) and crude marijuana are being

158 only abused psychotropic compounds, Delta(9)-tetrahydrocannabinol (THC) and heroin, on adult zebrafis

159 ins of marijuana with high levels of delta-9-tetrahydrocannabinol (THC) and low levels of cannabidiol

160 The involvement of dynorphin on Delta-9-tetrahydrocannabinol (THC) and morphine responses has be

161 We therefore compared effects of exposure to tetrahydrocannabinol (THC) and nicotine on DNA methylati

162 Delta(9)-Tetrahydrocannabinol (THC) and other cannabinoids are re

163 antagonist, blocks acute effects of Delta-9-tetrahydrocannabinol (THC) and other CB1 cannabinoid ago

164 ne, methadone, cocaine, heroin, codeine, and tetrahydrocannabinol (THC) and their major human metabol

165 Anandamide (AEA) and delta9-tetrahydrocannabinol (THC) are endogenous and exogenous

166 ntracellular effects resulting from Delta(9)-tetrahydrocannabinol (THC) binding without modifying beh

167 The cannabinoid Delta(9)-tetrahydrocannabinol (THC) disrupts HER2-CB(2)R complexe

168 Placental transfer of Delta9-tetrahydrocannabinol (THC) during pregnancy has the pote

169 Natural cannabinoids such as Delta(9)-tetrahydrocannabinol (THC) effectively modulate immune c

170 ng dose-dependent effects of chronic delta-9-tetrahydrocannabinol (THC) exposure on brain connectivit

171 Little data exists on effects of paternal tetrahydrocannabinol (THC) exposure prior to reproductio

172 csh) of adults following adolescent Delta(9)-tetrahydrocannabinol (THC) exposure.

173 tamine (MDEA), morphine, cocaine, and Delta9-tetrahydrocannabinol (THC) from a single blood spot.

174 Cannabidiol (CBD) and (9)-tetrahydrocannabinol (THC) have well documented immunomo

175 e neural mechanisms and durability of Delta9-tetrahydrocannabinol (THC) impact on threat processing i

176 e the effects of repeated exposure to Delta9-tetrahydrocannabinol (THC) in a mouse model of surgicall

177 to investigate whether exposure to Delta(9)-tetrahydrocannabinol (THC) in adolescent rats might enha

178 ontinuously rising concentrations of delta-9-tetrahydrocannabinol (THC) in cannabis (i.e., potency),

179 ry and the most sought psychoactive compound tetrahydrocannabinol (THC) in marijuana.

180 ta on the expected concentration of Delta(9)-tetrahydrocannabinol (THC) in the different types of can

181 murine tumors EL-4, LSA, and P815 to delta-9-tetrahydrocannabinol (THC) in vitro led to a significant

182 Chronic exposure to Delta9-tetrahydrocannabinol (THC) induces tolerance to cannabin

183 maging (MRI) to study the effects of delta-9-tetrahydrocannabinol (THC) infusion on brain blood flow

184 ined the acute and delayed effects of Delta9-tetrahydrocannabinol (THC) intoxication on susceptibilit

185 ies to attenuate certain aspects of Delta(9)-tetrahydrocannabinol (THC) intoxication.

186 Delta-9-tetrahydrocannabinol (THC) is known to modulate immune r

187 Chronic adolescent exposure to Delta-9-tetrahydrocannabinol (THC) is linked to elevated neurops

188 Delta(9)-tetrahydrocannabinol (THC) is the intoxicating constitue

189 (9)-tetrahydrocannabinol (THC) is the intoxicating constitue

190 Delta(9)-Tetrahydrocannabinol (THC) is the primary cannabinoid of

191 Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive c

192 Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive c

193 Currently, Delta(9)-tetrahydrocannabinol (THC) is used as the primary target

194 Like tetrahydrocannabinol (THC) itself, many synthetic cannab

195 positively with creatinine-normalized Delta9-tetrahydrocannabinol (THC) levels.

196 emic acid (AJA) is a synthetic analog of the tetrahydrocannabinol (THC) metabolite THC-11-oic acid; T

197 cularly vulnerable to the effects of Delta-9-tetrahydrocannabinol (THC) on brain structure.

198 ffects of the endocannabinoid agonist Delta9-tetrahydrocannabinol (THC) on executive function in 20 h

199 m mediate the inhibitory effects of Delta(9)-tetrahydrocannabinol (THC) on motor coordination.

200 d the effects of repeated exposure to Delta9-tetrahydrocannabinol (THC) on performance of spatial and

201 med to investigate the effect of oral Delta9-tetrahydrocannabinol (THC) on subjective and metabolic h

202 self-administration of cannabinoids delta-9-tetrahydrocannabinol (THC) or anandamide in squirrel mon

203 s containing high concentrations of Delta(9) tetrahydrocannabinol (THC) or cannabidiol.

204 ere available, 47 of 50 (94%) had detectable tetrahydrocannabinol (THC) or its metabolites in BAL flu

205 f cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negativ

206 Treatment with Delta(9)-Tetrahydrocannabinol (THC) resulted in the activation of

207 Exogenous cannabinoids such as tetrahydrocannabinol (THC) stimulate appetite and food i

208 d the effects of long-term/low-dose Delta(9)-tetrahydrocannabinol (THC) supplementation in simian imm

209 y consumed plant (phyto)cannabinoid Delta(9)-tetrahydrocannabinol (THC)(1).

210 cannabinoids (cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC)) on arrestin2-, Galpha(i/o)-,

211 The heterogeneous reaction of Delta(9)-tetrahydrocannabinol (THC), a major component of cannabi

212 bited potentiation produced by both Delta(9)-tetrahydrocannabinol (THC), a major psychoactive compone

213 Addition of Delta(9)-tetrahydrocannabinol (THC), a major psychoactive compone

214 ull agonist at CB(1) receptors, and Delta(9)-tetrahydrocannabinol (THC), a partial agonist, on the su

215 udy this phenomenon, we assessed how delta-9-tetrahydrocannabinol (THC), a primary psychoactive ingre

216 1 (CB1) is the principal target of Delta(9)-tetrahydrocannabinol (THC), a psychoactive chemical from

217 e effects of adolescent exposure to Delta(9)-tetrahydrocannabinol (THC), a psychoactive component of

218 e psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microgl

219 t binds the active constituent of marijuana, tetrahydrocannabinol (THC), and a postulated endogenous

220 psychoactive compound in marijuana, Delta(9)-tetrahydrocannabinol (THC), and its metabolites are emer

221 ell as exogenous cannabinoids such as Delta9-tetrahydrocannabinol (THC), are mediated by two subtypes

222 Phytocannabinoids, including Delta(9)-tetrahydrocannabinol (THC), are metabolized and inactiva

223 them have been determined, including delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD), and canna

224 (2-AG), anandamide (AEA), CP55,940, Delta(9)-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC+C

225 (UHPLC-MS/MS) for analysis of urinary Delta9-tetrahydrocannabinol (THC), cannabidiol and cannabinol,

226 ry actions of the phytocannabinoids Delta(9)-tetrahydrocannabinol (THC), cannabidiol, cannabichromene

227 may result in the incorporation of Delta(9)-tetrahydrocannabinol (THC), cannabinol (CBN), cannabidio

228 tting both detection and mapping of Delta(9)-tetrahydrocannabinol (THC), cannabinol (CBN), cannabidio

229 Unlike Delta(9)-tetrahydrocannabinol (THC), CBD does not act through the

230 ure to the psychoactive cannabinoid, Delta-9-tetrahydrocannabinol (THC), cerebral organoids exhibited

231 rawal symptoms following exposure to delta-9-tetrahydrocannabinol (THC), difficulties in obtaining ob

232 sychotropic component in marijuana, Delta(9)-tetrahydrocannabinol (THC), has also been shown to media

233 ow 10(-7) Torr, such as tetryl, cocaine, and tetrahydrocannabinol (THC), have been successfully detec

234 or its main psychoactive component Delta(9)-tetrahydrocannabinol (THC), impairs working memory, i.e.

235 sychoactive component of marijuana, Delta(9)-tetrahydrocannabinol (THC), is a signaling network that

236 circumvent the narcotic effects of Delta(9)-tetrahydrocannabinol (THC), many studies have concentrat

237 (alpha7nAChRs) modulate effects of Delta(9)-tetrahydrocannabinol (THC), marijuana's main psychoactiv

238 the active ingredient of cannabis, Delta(9)-tetrahydrocannabinol (THC), on sexual behavior in female

239 chronic exposure to vehicle solution, Delta9-tetrahydrocannabinol (THC), or the cannabinoid agonist R

240 nabinoids cannabichromene (CBC) and Delta(1)-tetrahydrocannabinol (THC), respectively] is predicted i

241 The marijuana cannabinoid, delta 9-tetrahydrocannabinol (THC), suppresses immunity to Legio

242 (9) -Tetrahydrocannabinol (THC), the active constituent of Ca

243 ent doses and treatment regimens of Delta(9)-tetrahydrocannabinol (THC), the main active ingredient i

244 strated that adolescent exposure to Delta(9)-tetrahydrocannabinol (THC), the main psychoactive compon

245 we show that adolescent exposure to Delta(9)-tetrahydrocannabinol (THC), the main psychoactive compon

246 ow co-administration of alcohol and Delta(9)-tetrahydrocannabinol (THC), the main psychoactive consti

247 The effects of Delta(9)-tetrahydrocannabinol (THC), the main psychoactive ingred

248 ctive component of tobacco, and (-)-Delta(9)-tetrahydrocannabinol (THC), the main psychoactive ingred

249 avioral effects similar to those of Delta(9)-tetrahydrocannabinol (THC), the main psychoactive ingred

250 Delta(9)-Tetrahydrocannabinol (THC), the major bioactive componen

251 In this study, we show that Delta-9-tetrahydrocannabinol (THC), the major psychoactive compo

252 Here we report that Delta9-tetrahydrocannabinol (THC), the major psychoactive compo

253 binoid receptor, the main target of Delta(9)-tetrahydrocannabinol (THC), the most prominent psychoact

254 Reinforcing effects of Delta(9)-tetrahydrocannabinol (THC), the primary active ingredien

255 er the influence of exogenously administered tetrahydrocannabinol (THC), the primary CB found in mari

256 The anxiolytic effects of delta(9)-tetrahydrocannabinol (THC), the primary psychoactive ing

257 Delta9-tetrahydrocannabinol (THC), the principal bioactive comp

258 Delta(9)-tetrahydrocannabinol (THC), the principal psychoactive i

259 (1)Rs) mediate the effects of triangle up(9)-tetrahydrocannabinol (THC), the psychoactive component i

260 Delta(9)-tetrahydrocannabinol (THC), the psychoactive component o

261 ngredient in chilli peppers, and by Delta(9)-tetrahydrocannabinol (THC), the psychoactive component o

262 behavior by laboratory animals with delta-9-tetrahydrocannabinol (THC), the psychoactive ingredient

263 tions of its main active ingredient, delta-9-tetrahydrocannabinol (THC), to be more harmful (in terms

264 ychoactive constituent in cannabis, Delta(9)-tetrahydrocannabinol (THC), was isolated in the mid-1960

265 Delta9-Tetrahydrocannabinol (THC), which is the main bioactive

266 DC), most patients report a history of using tetrahydrocannabinol (THC)-containing e-cigarette or vap

267 male, but not female, offspring of Delta(9)-tetrahydrocannabinol (THC)-exposed dams, a rat PCE model

268 armacological strategies to minimize Delta-9-tetrahydrocannabinol (THC)-induced neuropathology.

269 296 in hGlyR-alpha1 potentiation by Delta(9)-tetrahydrocannabinol (THC).

270 , and the psychotropic cannabinoid (-)Delta9-tetrahydrocannabinol (THC).

271 es containing the psychoactive drug Delta(9)-tetrahydrocannabinol (THC).

272 ijuana samples with higher concentrations of tetrahydrocannabinol (THC).

273 ne, methadone, cocaine, heroin, codeine, and tetrahydrocannabinol (THC).

274 is, specifically the psychoactive substance, tetrahydrocannabinol (THC).

275 oylecgonine (BE) and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THC-COOH) were shown to be strongl

276 metabolite of THC, 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THC-COOH) with chlorine.

277 nd the metabolites 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THC-COOH), 11-hydroxy-Delta(9)-tet

278 instance, the metabolite 11-hydroxy-Delta(9)-tetrahydrocannabinol (THC-OH).

279 The cannabinoid receptor agonist, Delta(9)-tetrahydrocannabinol (THC; dronabinol), decreases mariju

280 ed marijuana to orally administered Delta(9)-tetrahydrocannabinol (THC; dronabinol).

281 are mimicked by administration of (-)-Delta9-tetrahydrocannabinol (THC; the major psychoactive consti

282 Marijuana (hereafter "tetrahydrocannabinol [THC]") use has been associated wit

283 C. sativa), and major cannabinoid contents (tetrahydrocannabinol, THC; and cannabidiol, CBD), along

284 ecgonine (BE), and 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in this matrix.

285 endogenous cannabinoids, as well as Delta(9)-tetrahydrocannabinol, the main plant psychoactive consti

286 prenatal and adolescent exposure to delta-9-tetrahydrocannabinol, the major psychoactive component o

287 ns after the acute administration of delta-9-tetrahydrocannabinol, the primary psychoactive constitue

288 receptors also mediate the effects of Delta9-tetrahydrocannabinol, the primary psychoactive ingredien

289 Here, we found that Delta(9)-tetrahydrocannabinol, the psychoactive ingredient of can

290 rs CB(1) and CB(2) are activated by Delta(9)-tetrahydrocannabinol, the psychoactive ingredient of can

291 to mitigate the central effects of Delta(9)-tetrahydrocannabinol through the CB1 receptor.

292 sulting in a change in the ratio of Delta(9)-tetrahydrocannabinol to cannabidiol from 14 times in 199

293 abinoids such as the marijuana component (9)-tetrahydrocannabinol, to heterotrimeric G12/G13 proteins

294 everal weeks after the cessation of Delta(9)-tetrahydrocannabinol treatment.

295 ore study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis naive co

296 ore study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive co

297 tic remodeling that can occur after Delta(9)-tetrahydrocannabinol use.

298 e range of 0.05-60 mg/kg, and the content of tetrahydrocannabinol varied between 3.23 and 69.5 mg/kg.

299 in the nucleus accumbens induced by Delta(9)-tetrahydrocannabinol was blocked in mice lacking the Hcr

300 We additionally found that Delta9-tetrahydrocannabinol, which has been shown to attenuate